OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2020-12-31-accounts

Company Number 06884476

YORK AGAINST CANCER

A company limited by guarantee and A registered charity number 1130835

REPORT AND ACCOUNTS

For the year ended 31 December 2020

HPH Chartered Accountants 54 Bootham York YO30 7XZ

YORK AGAINST CANCER

CONTENTS

Page
Founders 1
Chairman’s Report 2
Trustees’ Report 3 ‐ 15
Auditor’s Report 16 – 19
Statement of Financial Activities 20
Balance Sheet 21
Cash Flow Statement 22
Notes to the Financial Statements 23 ‐ 33

YORK AGAINST CANCER

Founders

Prof Stephen Leveson Mr John Craven Prof Colin Garner

www.yorkagainstcancerorg.uk 1

YORK AGAINST CANCER

CHAIRMAN’S REPORT 2020

I am sure I don’t need to remind anybody about the impact Covid 19 has had during the year. It has had a significant effect on the day to day work that we all undertake, including the work of the Charity.

During the year our small and dedicated workforce led by General Manager Julie Russell remained to the fore in ensuring we delivered on our promise to support those in need, both individuals and families whenever circumstances allowed, and I am grateful for their dedication during what has been a very difficult time.

As you will be aware we have been forced to make a number of difficult decisions in the short term due to the on‐going restrictions, but we look forward to the Charity being back and fully functioning in the not too distant future.

In the meantime, work continues, and while some events are on hold, the need to strategically plan for our future requirements goes on to ensure we remain in a position to continue the important services for people touched by cancer – services that will be even more important as we consolidate and expand on the outstanding work undertaken in the many areas that the Charity is involved in.

Our move to our new shop and offices at Vangarde Monks Cross did not take place as expected, and the continuing delay has been a source of frustration. The move is now planned in 2021 and will hopefully have happened by the time you read this. This will put the Charity far more central from an awareness point of view.

A number of Board member colleagues have retired this year, and we would like to record our thanks to Keith Hayton, Pat Kay, Gordon Topping and John Yeomans for the many years of hard work and dedication they have given. We also sadly lost a number of supporters and volunteers, and our thoughts go out to their families, and we wish them well for the future.

Every one of them supported the day to day work of the Charity, and our volunteers, our staff and all those who help in their own way enable us to continue to provide the important services and funding for research that the Charity is recognised for.

Despite the many restrictions, our minibus service was able to operate in difficult conditions at times, and our thanks go to Ian and Neil for providing this important service when many other cancer services were severely curtailed by the NHS. Working in the office, promoting the Charity or driving our minibus our small and important band of dedicated staff are the daily face of York Against Cancer, and ably supported by our committed army of volunteers, the Charity remains in good hands.

We have missed the regular involvement of our wonderful volunteers, but we know when things start to return to normal you will once again provide support in our shops and at numerous events throughout the year.

Ian Yeowart Chair York Against Cancer

www.yorkagainstcancerorg.uk 2

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

The Directors (who are also the Trustees of the Charity and are listed below) are pleased to present their report of the Charitable Company for the year ended 31 December 2020.

Objectives and activities

The objects of the Charity are to raise funds to:

  1. Foster and promote joint research between clinicians and research scientists in York and wider area and, by encouraging a more effective exchange of ideas and information, to advance the alleviation and cure of cancer.

  2. Support treatment of cancer patients at York Hospital and the local area.

  3. Fund education and information about cancer for patients and their families and the wider public.

The Trustees believe they have complied with the duty in section 4 of the 2006 Charities Act to have due regard to guidance published by the Charity Commission in respect of public benefit.

Aims and strategies

The Charity aims to provide support to cancer patients and the community through the: ‐

Achievements and performance

Research

Jack Birch Unit (University of York)

The Charity is committed to another 4 years supporting the work of the Jack Birch Unit. The roles supported by York Against Cancer are: ‐

Director of the Jack Birch Unit Assistant Director Laboratory technician Administrative assistant

Research Fellow in Informatics at the Jack Birch Unit is also being supported from 2019 to 2024. A more in‐depth report of the work of the Unit is detailed on pages 7 and 8.

Developments in the Year and Future Planning

The Board have continued their consistently adopted policy of only making commitments when the finance for these is already in place. The Board are mindful of the responsibility of ensuring that the generous donations received are used in the most effective manner possible to meet with the aims of the charity. With a sudden influx of a large legacy in 2016 the board established a Finance Sub‐group to consider the most effective way to manage the funds for the future of the charity. The Board has agreed with the recommendations of the sub‐group that a significant proportion of funds should be invested to provide for both future security of the charity and to ensure that the capital is used most effectively and to be available when future projects are considered and to ensure that the long‐term plans and services the charity provides can be continued into the foreseeable future.

www.yorkagainstcancerorg.uk 3

YORK AGAINST CANCER

CHAIRMAN’S REPORT 2020

I am sure I don’t need to remind anybody about the impact Covid 19 has had during the year. It has had a significant effect on the day to day work that we all undertake, including the work of the Charity.

During the year our small and dedicated workforce led by General Manager Julie Russell remained to the fore in ensuring we delivered on our promise to support those in need, both individuals and families whenever circumstances allowed, and I am grateful for their dedication during what has been a very difficult time.

As you will be aware we have been forced to make a number of difficult decisions in the short term due to the on-going restrictions, but we look forward to the Charity being back and fully functioning in the not too distant future.

In the meantime, work continues, and while some events are on hold, the need to strategically plan for our future requirements goes on to ensure we remain in a position to continue the important services for people touched by cancer – services that will be even more important as we consolidate and expand on the outstanding work undertaken in the many areas that the Charity is involved in.

Our move to our new shop and offices at Vangarde Monks Cross did not take place as expected, and the continuing delay has been a source of frustration. The move is now planned in 2021 and will hopefully have happened by the time you read this. This will put the Charity far more central from an awareness point of view.

A number of Board member colleagues have retired this year, and we would like to record our thanks to Keith Hayton, Pat Kay, Gordon Topping and John Yeomans for the many years of hard work and dedication they have given. We also sadly lost a number of supporters and volunteers, and our thoughts go out to their families, and we wish them well for the future.

Every one of them supported the day to day work of the Charity, and our volunteers, our staff and all those who help in their own way enable us to continue to provide the important services and funding for research that the Charity is recognised for.

Despite the many restrictions, our minibus service was able to operate in difficult conditions at times, and our thanks go to Ian and Neil for providing this important service when many other cancer services were severely curtailed by the NHS. Working in the office, promoting the Charity or driving our minibus our small and important band of dedicated staff are the daily face of York Against Cancer, and ably supported by our committed army of volunteers, the Charity remains in good hands.

We have missed the regular involvement of our wonderful volunteers, but we know when things start to return to normal you will once again provide support in our shops and at numerous events throughout the year.

Ian Yeowart Chair York Against Cancer

www.yorkagainstcancerorg.uk 2

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

The Directors (who are also the Trustees of the Charity and are listed below) are pleased to present their report of the Charitable Company for the year ended 31 December 2020.

Objectives and activities

The objects of the Charity are to raise funds to:

  1. Foster and promote joint research between clinicians and research scientists in York and wider area and, by encouraging a more effective exchange of ideas and information, to advance the alleviation and cure of cancer.

  2. Support treatment of cancer patients at York Hospital and the local area.

  3. Fund education and information about cancer for patients and their families and the wider public.

The Trustees believe they have complied with the duty in section 4 of the 2006 Charities Act to have due regard to guidance published by the Charity Commission in respect of public benefit.

Aims and strategies

The Charity aims to provide support to cancer patients and the community through the: -

Achievements and performance

Research

Jack Birch Unit (University of York)

The Charity is committed to another 4 years supporting the work of the Jack Birch Unit. The roles supported by York Against Cancer are: -

Director of the Jack Birch Unit Assistant Director Laboratory technician Administrative assistant

Research Fellow in Informatics at the Jack Birch Unit is also being supported from 2019 to 2024. A more in-depth report of the work of the Unit is detailed on pages 7 and 8.

Developments in the Year and Future Planning

The Board have continued their consistently adopted policy of only making commitments when the finance for these is already in place. The Board are mindful of the responsibility of ensuring that the generous donations received are used in the most effective manner possible to meet with the aims of the charity. With a sudden influx of a large legacy in 2016 the board established a Finance Sub-group to consider the most effective way to manage the funds for the future of the charity. The Board has agreed with the recommendations of the sub-group that a significant proportion of funds should be invested to provide for both future security of the charity and to ensure that the capital is used most effectively and to be available when future projects are considered and to ensure that the long-term plans and services the charity provides can be continued into the foreseeable future.

www.yorkagainstcancerorg.uk 3

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

The members of the Board are constantly looking at the needs of cancer patients and cancer services in the area to see where an investment could provide a significant improvement to the cancer services.

The delay in the Monks Cross development will mean that the charity will remain on the Huntington site for the present and the date for moving will be 2021.

The charity has continued to benefit from legacies during the year which give a great boost to the charity’s funds, and we are immensely grateful to these generous people. Legacy income is, unpredictable and is another reason why the charity must husband its resources in the most effective way to enable the services we provide to both continue and develop.

Mobile Chemotherapy Unit

In recent years, the charity has worked on raising its profile, both locally and in a wider area of North and East Yorkshire with a successful rebranding exercise. With the Mobile Chemotherapy Unit project coming to fruition which takes chemotherapy services to the wider areas of the York Teaching Hospital, at Malton, Selby, Scarborough and Bridlington, it has enabled the charity to widen its reach. This has helped thousands of patients the time-consuming and tiring journeys to the hospital in York. In its first full year of operation the unit has been very well received by both medical staff and patients.

It also significantly increased the capacity of the hospital to provide the chemotherapy services to meet the needs of patients. Our fundraisers have been actively raising funds to help with the running costs of the enterprise.

Respite Properties

The holiday homes at Filey and Whitby continue to provide a welcome break, each in its own special environment. The many letters of appreciation we receive are an indication of how much a short break in these luxurious surroundings are appreciated. The YAC board is looking into extending this service through exploring opportunities to buy an additional property.

Dermatoscope Project

The dermatoscope project, launched 3 years previously, has continued to expand and develop and is really beginning to make an impact to help the early diagnosis of skin cancer, by which these specially designed photo units have been supplied to all GP practices in the area, has made the early diagnosis of skin cancer not only easier and more efficient but has greatly reduced the waiting time for patients to see a consultant. This model of this project has been picked up by other areas and is now being replicated in other hospitals

Supporting patients

The Health Care Assistant have continued to provide support for families affected by cancer. These appointments are made in conjunction with the NHS to provide support for patients and their families; support which is not available through the normal NHS services. This year complementary therapy arranged through the Cancer Care Centre has been significantly affected by Covid-19 and patients have been offered complementary therapy and other services virtually. Our minibus service has also been affected by Covid, for a few months it was not able to run but as soon as the restrictions allowed it resume, however, with a restricted number of passengers. It continues to be an excellent and muchvalued service of transporting patients to St. James’ Hospital.

www.yorkagainstcancerorg.uk 4

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Health Welfare Advisor

The charity continues to support the Citizens Advice Bureau in their work with cancer patients at Scarborough hospital: this work provides support for those having cancer treatment and based at Scarborough to ensure that they receive all the help to which they are entitled.

Management Report

The small team of hardworking office staff deal effectively with all aspects of the day-to-day operation of the charity, and it is worth noting that during 2020 that there has been an inevitable impact on fundraising and charity/staff/board morale and the charity have striven to deal with those demands and risen to meet the challenges head on.

The teams work is sometimes challenging as they deal with people facing cancer and on occasions this can impact on their resolve, they deal with this together and their teamwork is impressive. The team are friendly and often are found smiling. The way it is possible for our manager and her staff to respond quickly to any requests or challenges is a key strength for York Against Cancer as a local charity.

Minibus

We continue to get very encouraging feedback from the users of the minibus, the Whitby apartment and the Filey holiday home. The members of staff have worked in close co-operation with the Cancer Care Centre and this has enabled the apartment to be used by some very deserving cases. The thoughtful and kind approach of our minibus drivers has also again been very much appreciated.

The people supported by York Against Cancer

Although the people directly employed by the charity are those listed above there are, in addition, those who are employed directly by others but whose salary costs are paid by York Against Cancer. All these posts are supported as the work done by these people directly enables the charity to achieve its goals. These posts are itemised below and illustrate the range of activities supported by the Board:

JBU - Director of the Jack Birch Unit

Assistant Director

Laboratory technician

Administrative assistant

Administrators at the Cancer Care Centre (3 staff covering 37 hours)

Health Care Assistant (part-time)

Complementary therapists (one full-time equivalent)

Clinical Research Nurse and Assistant posts at York Hospital (two-year funding to end of 2021)

Research Fellow in Informatics at the Jack Birch Unit (from 2019 to 2024)

All these supported positions are initially given for a fixed term (usually two or three years) and then reviewed by the Board. This is done to ensure that the money so generously raised by our supporters is used in the most efficient way.

www.yorkagainstcancerorg.uk 5

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Education

The Cancer Awareness and Prevention group continues to work to spread information about cancer across as wide a range of the public as possible with an emphasis on young people. The work of the group is reported separately on page 9.

Fundraising

The retail outlets, at Huntington and the Hospital have continued to be an invaluable source of income and the hospital shop provides a very useful ‘shop front’ for the charity. The sterling work done by our volunteers; and our staff in the office has yet again given up many hours in the evening and at weekends to help raise funds and spread the message about York Against Cancer. The links with the local business community have again proved a great benefit to the charity. With all these efforts from our employed staff and volunteers the charity is able to provide more much-needed support to many in the local community. Compared to many charities, it is remarkable to consider that York Against Cancer does not employ a fundraiser as such and we are totally reliant on our supporters and volunteers for the funding we receive.

York Against Cancer is committed to maintaining high standards of fundraising and retail activity. The Charity is registered with the Fundraising Regulator. The Charity has recognised and begun to put in place a comprehensive policy for fundraising. The Charity does not use any third parties to act on its behalf in relation to fundraising. No complaints were received by the charity during 2019 in relation to its fundraising activities. For further information on fundraising activities undertaken during the year see page 10.

www.yorkagainstcancerorg.uk 6

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Jack Birch Unit of Molecular Carcinogenesis Annual Report 2020

What a year that was! I don’t think there’s anyone unaffected by the pandemic, but it’s not all been bad news on the JBU front.

Back in January 2020 I attended the University of York Graduation Ceremony where York Against Cancer were conferred onto the College of Benefactors as a founding member. In late February, I visited India with a couple of University colleagues under the Global Challenges Research Fund programme to explore potential collaborations. Here we met many enthusiastic researchers with common interests in carcinogenesis mediated through contamination of water courses by heavy metals, such as cadmium. Then, just before lockdown, Simon Baker attended the Bladder Cancer Translational Meeting in Birmingham to present his work towards a new personalised therapy for Bladder Cancer.

Then came lockdown. Amazingly, Simon carried on lab work throughout the first lockdown as he had ongoing experimental work. This research resulted in a publication in a leading scientific journal and was featured on the front cover. The paper describes the “signatures” left by carcinogens and brings important new insight for understanding the causes of bladder cancer.

Although lockdown meant we could not travel, we were able to participate remotely by zoom in various scientific conferences, including the International Bladder Cancer Network in October (at which Simon presented). Our clinical fellow, Debora Morgante presented her research to the Biomaterials and Tissue Engineering Group meeting and won first prize. We also “Zoomed” into schools to spread the word about York Against Cancer, our research and the possibilities of scientific careers.

Of our staff and students. Jen returned from maternity leave in April; Edgar (Zhen Liu) returned to China to finish writing up his PhD and our York Against Cancer PhD student, Tom Crighton submitted his PhD thesis titled “Hippo and Sonic Hedgehog signalling pathway modulation of human urothelial tissue homeostasis”. We were joined by Ryan Ellis as our latest York Against Cancer-funded student and by Ben Jarvis, a one-year Masters by Research student. Vlad Ungureanu also joined us as a PhD student based between the Departments of Electronic Engineering and Biology, and jointly supervised by Andrew Mason, among others. As our York Against Cancer-funded Independent Research Fellow, Andrew continues to develop the informatics capability of the JBU, including hiring Katie Skinner for one-year as a bioinformatician before she starts a PhD in cancer bioinformatics in the USA in Autumn 2021.

www.yorkagainstcancerorg.uk 7

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

We missed running our cake stalls to raise funds for York Against Cancer but managed to raise £380 through the – you’ve guessed it – zoom quiz that Andrew Mason ran in November.

The JBU group carried on having weekly research meetings on zoom throughout the year.

As always, we are extremely grateful for research support from York Against Cancer, who help towards funding several salaries of staff in the Jack Birch Unit – plus the research fellowship of Dr Andrew Mason. Finally, I would like to acknowledge the invaluable contribution that our scientific and clinical collaborators make to the quality and output of our research.

Professor Jenny Southgate, Director, Jack Birch Unit of Molecular Carcinogenesis, University of York

www.yorkagainstcancerorg.uk 8

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Cancer Education and Awareness Team

Annual Report 2020

I became interim chair of the committee in January, following John Molyneux who has served for many years with the last 6 years as chair. John has been very enthusiastic and hardworking and was particularly supportive when I joined the committee. Last year also saw Steve Leveson and Keith Hayton stepping down. Both have been important members of our committee as well as key figures in the history of York Against Cancer.

I’m very pleased to report the activities of the committee for 2020 which, of course, were overshadowed by the Covid-19 Pandemic. The committee has met virtually, via Zoom, and many of our efforts have been adversely affected. With this in mind, I would like to outline our progress in 2020.

Following Simon Baker’s hard work, the Enthuse partnership with local schools was due to start in early 2020. However, the Covid-19 pandemic struck and schools were forced to close. Throughout the year education has been severely disrupted and the project could not get underway. The funding provided will be rolled forward from the point that teachers are able to focus on the scheme.

Simon has also discussed with York University the possibility of making the Campus smoke free. Unfortunately, for logistical reasons, this could not be implemented. However, it was agreed to stop the sale of tobacco on Campus.

Because of school closures, we were unable to carry out our annual delivery of sun hats and sun awareness leaflets to primary schools. We will resume this important activity as soon as permitted.

Julie Russell and I continued our regular meetings [again virtual of course] with Dr. Dan Cottingham, the lead GP for cancer care at the CCG. It has been very helpful to share information regarding, for example, cancer screening programmes and the very encouraging success of the use of YAC funded dermato-scopes in Primary Care.

Again, unfortunately we were unable to hold our annual cancer awareness day in York city centre due to Covid-19 restrictions.

Lynn Bartram who sits on the committee is a Primary School Head. She highlighted the issue of providing support to children who are affected by cancer either through family or other contacts. Julie Russell and Lynn worked together to define a collection of age specific books which can be supplied to children requiring help. York Against Cancer will fund the supply of these books into schools.

In November the committee held a virtual brain-storming meeting to bring forward ideas which might form a development plan for 2021. Lively and interesting discussion resulted in suggestions that ranged from local and online media, through theatre workshops in schools to a medicinal herb garden. All projects to raise cancer awareness in our community.

Following a change of the York Against Cancer Terms of Reference in early 2020, I stood as interim chair of the committee through 2020. Lynn Bartram, who also sits on the main board, kindly agreed to become chair of the Education and Awareness committee in January 2021.I’m sure that her knowledge and experience in education will be invaluable in taking the work of the committee and York Against Cancer forward.

Stuart Parker - Interim Chair

www.yorkagainstcancerorg.uk 9

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Fundraising report 2020

As we started 2020, we could not have envisaged what we were facing regarding the pandemic, internationally, nationally, and locally. As the country went into lock down it meant that all our planned fundraising events were postponed. It was obvious quite early on that the charities fundraising income would be severely impacted by the situation but as a health related and caring charity our priority was to do everything to keep our fundraisers, supporters, volunteers, and staff safe.

Our regular fundraisers were contacted, new dates were discussed and diarised. This demonstrated that our faithful band of fundraisers were not going to let a pandemic stop them supporting us in the future. This is heart-warming and shows what our charity means to the people of York and the wider area of North and East Yorkshire.

Some fundraisers were determined to continue and either adapted their events to be Covid friendly or in fact changing their event to become a virtual event. It has made us and many of our fundraisers think about fundraising in a different way and in fact given it another dimension and virtual events are more than likely a thing of the future.

The situation has also given us the time to consider our fundraising methods; what we do, how we do them and in fact are there better, more efficient, and more profitable ways of fundraising.

Here are a few examples of how fundraising has continued during 2020

In conclusion, 2020 has been a difficult year for us but we are optimistic about the future and we look forward to working with our fundraisers and supporters long into the future.

Thank you to everyone who have fundraised and to those also who have plans to raise money for us we really do appreciate you all – thank you for your contributions.

Julie Russell General Manager

www.yorkagainstcancerorg.uk 10

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Structure, Governance and Management

The charity was incorporated on 22 April 2009 and its governing document is the memorandum and articles of association. The charity is a company limited by guarantee.

The charity is governed by a Board of Directors, supported by working groups as required. The Board members are all Trustees and include Officers of the Charity.

The Board meets four times a year and the various working groups meet as required during the year.

The members of the Board are volunteers. New Board members are elected by the existing members up to a maximum of twelve in total.

Trustee Induction and Training

New Trustees are briefed on their legal obligations under charity law, the committee and decisionmaking processes, the business plan and recent financial performance of the Charity. During their induction they meet key employees and other trustees. Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role. At the end of each three tenure the trustees are required to update their trustee training.

Organisational Structure

The Board delegates the day-to-day management of the affairs of the Charity to one Board member, Keith Hayton, who serves as the Honorary Administrator (resigned 7 July 2020). This responsibility was taken on by Tarnia Hudson (commenced July 2020).

The members of staff employed by the Charity during the year were:

Julie Russell General Manager
Heather Atkinson Office & Accounts Manager
Lauren Hudson Personal Assistant to General Manager from 9thMarch 2020
Nicola Doherty P.A. to General Manager until 7thFebruary 2020 – Office &
Volunteer coordinator 10thFebruary 2020
Helen Watkinson Retail Manager part-time until 7thFebruary 2020, full-time
from 10thFebruary 2020
Francine Clee PR & Communications Officer (part-time)
Ian Stephenson Minibus Driver (part-time)
Neil Johnson Minibus Driver (part-time)

Board membership

In March 2013 the Board adopted, by unanimous agreement, a protocol to introduce a three-year rule from that date. Board members continue to actively seek new trustees, taking into consideration a good mix of professional skills including business, education and medical. A term of office for a director is 3 years, after which time he/she may be re-elected for a further 3-year term up to a maximum of 9 years in total (details of current terms of office available on request).

Remuneration of key personnel

All members of staff employed by the charity have an annual appraisal in January following which salaries are set for the following 12 months. The appraisals are carried out by the General Manager.

No Board member received any income or expenses for their work for the charity.

www.yorkagainstcancerorg.uk 11

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Related parties

The Charity owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited, a company registered in England and Wales. The subsidiary is used for the raising of funds for the Charity through the sale of bought in goods through the Charity’s two shops.

Risk management

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the Charity and continues to take measures to reduce those risks to an acceptable minimum. The policy of only making new commitments when the funds are in hand is a very practical way of eliminating unnecessary financial risks. By its very nature a charity relies on fundraising, donations and legacies which can vary a great deal. Ongoing commitments are to our staff, to a range of time limited research and care projects and to the leasehold of the new premises at the LNER community stadium with a delayed move in 2021. The move will provide greater storage and office space and a retail outlet with a good footfall. The trustees have calculated the move is necessary for the further development of the work of the charity. It should be emphasised that supporting staff not directly employed by York Against Cancer is always done on a time-limited basis (typically two years) which is renewed as appropriate provided funds are available.

The Board is very mindful that the charity has a substantial reserve of funds and seeks to find effective ways in which these can be utilised to fulfil the aims of York Against Cancer, whilst at the same time investing some funds to provide for future security.

Financial review and polices

The Charity’s funds in 2020 increased by £24,290. Large investment gains have reduced the deficit significantly. Prior to any adjustment for investments, the Charity made a deficit of £146,787 (2019 deficit of £498,309). The charity was expecting a deficit as it utilises some of the excess free reserves for charitable purposes.

The principal funding sources are fund-raising, the trading shops, donations, legacies and members’ subscriptions. Gross income in 2020 amounted to £389,859 (2019 £1,708,583). These funds support the key objectives of the Charity, namely, to fund clinical research, to support people with cancer and to fund education about the disease.

£163,187 was committed on project expenditure, to support the Charity’s ongoing projects. Due to COVID-19 there were limited additional projects taken on this year. The detail of funding of projects can be found in note 6.

Investment powers and policy

The Trustees have a general power of investment and so have the discretion to invest in such investment assets as they see fit. The Trustees have set a policy that sufficient of the ‘free reserves’ should be invested to retain a reasonable liquidity to meet grant commitments.

Our policy is a medium low risk approach for the growth of the portfolio of investments. The investment managers have discretion about how the investments are managed within the policy parameters set by the Trustees.

www.yorkagainstcancerorg.uk 12

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

The Investment Group oversees the investment management of the Charity’s funds. The services of HSBC Private Bank and Ruffer were retained as investment managers during 2020. Funds not invested are held on deposit to earn interest.

The total return on the investment portfolio managed by HSBC for the year ended 31 December 2020, before fees, was 0.43% (2019 14.67%). The total return on investment portfolio managed by Ruffer for the year ended 31 December 2020, before fees, was 11.8% (2019 6.8%).

Reserves Policy

The reserves policy is to generate a stable and sustainable return to fund grant making, to ensure continued financial security and to provide for contingencies. Cash reserves are accumulated before making a binding commitment to fund a project due to the nature and uncertainty of the income streams. The total funds held as at 31 December 2020 are £4,282,644 (2019 £4,258,354).

The Board is very mindful that the charity has a substantial reserve of funds at present after the receipt of some large legacies. The board is actively seeking to find effective ways in which these can be utilized to fulfil the aims of York Against Cancer, whilst at the same time investing some funds to provide for future security.

Undesignated Fund

These are free reserves retained to provide working capital and funds for future projects. At the end of the financial year, the free reserves were £3,503,531 (2019 £3,434,524) accumulated largely due to the receipt of several generous legacies, which by their very nature are unpredictable. The level of free reserves will enable the Charity to give significant support to worthwhile projects which make a measurable impact.

Designated Funds

Designated funds are part of the unrestricted funds which trustees have earmarked for assets held for the use in the charity and specific projects. At the year end, The Charity had consolidated designated funds of £635,088 (2019 £667,862) details of which are given in Note 16 of the financial statements.

Restricted Funds

Restricted funds represent monies raised by the Charity from public appeals for specific projects. At the year end, the Charity had restricted funds of £144,025 (2019 £155,968) details of which are given in Note 17 to the financial statements.

COVID-19 has had a significant impact on donations and fundraising since April 2020 as events have been either cancelled or postponed. The charity has significant reserves brought forward and these will be used to help support the charity adapt where needed and keep its on-going commitments.

www.yorkagainstcancerorg.uk 13

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Directors and Trustees Responsibilities

The purpose of this statement is to distinguish the Directors’ and Trustees’ responsibilities for the financial statements from those of the auditors as stated in their report.

Company and charity law require the Directors and Trustees to prepare financial statements which give a true and fair view of the Charitable Company’s state of affairs at the end of its financial activities for that year. In preparing those financial statements the Trustees are required to:

The Directors and Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Charitable Company and enables them to ensure that the financial statements comply with the Companies Act 2006 and applicable charity law. They are also responsible for safeguarding the assets of the Charitable Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Directors and Trustees are aware:

Approved by the Board on 14 September 2021 and signed on its behalf by:

Ian Yeowart Director and Trustee

www.yorkagainstcancerorg.uk 14

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Reference and administrative details

Registered Charity number 1130835 Company Limited number 06884476 by Guarantee

Principal Office and Trading Address

31 - 33 North Moor Road Huntington York YO32 9QN

Company Secretary Julie Pamela Russell

Directors and Trustees Andrew Proctor Angela Darby Rachel Goddard Michael John Stower William Mark Sessions Ian Yeowart Sarah Wearing Tarnia Hudson Prof Stephen Leveson Michael Patrick Shepherd

Dr Lynn Bartram (appointed September 2020) Michael Sweet (appointed September 2020) Robert Onyett (appointed September 2020) John Francis Yeomans (resigned 7 July 2020) Edward Keith Hayton (resigned 7 July 2020) Patricia Anne Kay (resigned 7 July 2020) Gordon Andrew Topping (resigned February 2020)

Trustee’s protocol / length of service document available on request

Accountants HPH Auditors Townends Accountants LLP
Chartered Accountants Chartered Accountants
54 Bootham Fulford Lodge
York 1 Heslington Lane
YO30 7XZ Fulford
York
YO10 4HW
Bankers National Westminster Bank Solicitors Harrowells
1 Market Street Moorgate House
York Clifton Moorgate
YO1 8SR York
YO30 4WY
Investment Advisors HSBC Global Asset Ruffer LLP
Management 80 Victoria Street
78 St James’s Street London
London SW1E 5JL
SW1A 1EJ

www.yorkagainstcancerorg.uk 15

YORK AGAINST CANCER

COMPANY LIMITED BY GUARANTEE

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2020

Opinion on financial statements

We have audited the financial statements of York Against Cancer for the year ended 31 December 2020, which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement, the Income and Expenditure Account and related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards including Financial Reporting Standard FRS102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the Charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustee's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the original financial statements were authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

www.yorkagainstcancerorg.uk 16

YORK AGAINST CANCER

COMPANY LIMITED BY GUARANTEE

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2020

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matter on which we are required to report by exception

In the light of the knowledge and understanding of the Charity and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees’ Annual Report.

We have nothing to report in respect of the following matters where the Companies Act 2006 required us to report to you if, in our opinion:

Responsibilities of the trustees

As explained more fully in the trustees’ responsibilities statement set out on page 14, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the Charity’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the Charity or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

www.yorkagainstcancerorg.uk 17

YORK AGAINST CANCER

COMPANY LIMITED BY GUARANTEE

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2020

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

www.yorkagainstcancerorg.uk 18

YORK AGAINST CANCER

COMPANY LIMITED BY GUARANTEE

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2020

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the Charity's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charity's members those matters we are required to state to them in an auditors report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charity's members as a body, for our audit work, for this report, or for the opinions we have formed.

………………………………………………..

Paul Sharpe FCA (Senior Statutory Auditor)

For and on behalf of Townends Accountants LLP

Chartered Accountants & Statutory Auditor

Date: 14 September 2021

Carlisle Street Goole East Riding of Yorkshire DN14 5DX

www.yorkagainstcancerorg.uk 19

YORK AGAINST CANCER

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES AND INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 DECEMBER 2020

Note
Income and endowments from:
Donations and legacies
2
Other trading activities
3
Investments
4
Total
Expenditure on:
Raising funds
5
Charitable activities
6
Total
Net expenditure
before losses on investments
Net gains on investments
11
Net income/(expenditure)
Transfers between funds
16
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Total funds carried forward		 General
Designated
Fund
Funds
£
£
182,105
-
157,863
-
49,291
-
389,259
-
156,656
-
286,513
80,934
443,169
80,934
(53,910)
(80,934)
171,077
-
117,167
(80,934)
(48,160)
48,160
69,007
(32,774)
3,434,524
667,862
3,503,531
£
635,088
£
Unrestricted		 Restricted
Funds
£
600
-
-
600
-
12,543
12,543
(11,943)
-
(11,943)
-
(11,943)
155,968
144,025
£		 Year ended
31 Dec
2020
£
182,705
157,863
49,291
389,859
156,656
379,990
536,646
(146,787)
171,077
24,290
-
24,290
4,258,354
4,282,644
£		 Year ended
31 Dec
2019
£
1,365,532
274,018
69,033
1,708,583
186,092
2,020,800
2,206,892
(498,309)
351,402
(146,907)
-
(146,907)
4,405,261
4,258,354
£

The notes on pages 23 to 33 form part of these financial statements.

20

YORK AGAINST CANCER

(Registration number: 06884476)

BALANCE SHEET AS AT 31 DECEMBER 2020

FIXED ASSETS
Tangible Fixed Assets
12
Investments
11
CURRENT ASSETS
Stock
Debtors
13
Cash at Bank and in Hand
CREDITORS: amounts falling due
within one year
14
TOTAL ASSETS LESS CURRENT
LIABILITIES
CREDITORS: amounts falling due
after one year
15
NET ASSETS
THE FUNDS OF THE CHARITY
Unrestricted
Undesignated
18
Designated
16,18
Restricted
17,18
TOTAL CHARITY FUNDS
NET CURRENT ASSETS
Note		 Charity
2020
£
573,526
3,741,011
4,314,537
-
551,936
827,681
1,379,617
487,559
892,058
5,206,595
961,016
£ 4,245,579
3,478,282
623,272
144,025
£ 4,245,579		 Consolidated
2020
£
585,342
3,741,010
4,326,352
55,295
462,285
898,835
1,416,415
499,107
917,308
5,243,660
961,016
£ 4,282,644
3,503,531
635,088
144,025
4,282,644
£		 Charity
2019
£
589,541
3,548,077
4,137,618
-
783,450
1,168,245
1,951,695
615,171
1,336,524
5,474,142
1,252,278
£ 4,221,864
3,409,375
656,521
155,968
£ 4,221,864		 Consolidated
2019
£
600,882
3,548,076
4,148,958
57,259
694,330
1,237,711
1,989,300
627,626
1,361,674
5,510,632
1,252,278
£ 4,258,354
3,434,524
667,862
155,968
£ 4,258,354

Approved by the Trustees on 14 September 2021 and signed on its behalf by:

S B Wearing Director and Trustee

The notes on pages 23 to 33 form part of these financial statements.

21

YORK AGAINST CANCER CONSOLIDATED CASHFLOW STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2020

Note
Cash flows from operating activities:
Net cash provided by/(used in) operating activities
21
Cash flows from investing activities:
Dividends, interest and rents from investments
Purchase of property, plant and equipment
Proceeds from sales of investments
Purchase of investments
Net cash provided by/(used in) investing activities
Change in cash and cash equivalents in the
reporting period
Cash and cash equivalents at the beginning of
the reporting period
Cash and cash equivalents at the end of
the reporting period		 2020
£
(363,320)
49,291
(2,990)
1,095,488
(1,117,345)
24,444
(338,876)
1,237,711
£ 898,835		 2019
£
6,206
69,033
(9,926)
1,295,325
(825,288)
529,144
535,350
702,361
£ 1,237,711

The notes on pages 23 to 33 form part of these financial statements.

22

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

1. ACCOUNTING POLICIES

Legal entity

York Against Cancer is regulated by the Charities Commission (1130835), limited by guarantee and is registered in England and Wales. The address of the registered office and principal place of business is 31 - 33 North Moor Road, Huntington, York, YO32 9QN.

Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The consolidated accounts include the results of the Charitable Company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

No separate SOFA has been presented for the Charitable Company alone as permitted by the SORP.

The Charitable Company constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in UK Sterling pounds (£).

Going Concern

The Charitable Company has cash resources and has no requirement for external funding. The cash and investments held are sufficient to see the Charitable Company through the financial impact of COVID-19. The Directors and Trustees have a reasonable expectation that the Charitable Company has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting appropriate in preparing the annual financial statements.

Income

Donations and legacies

Credit is taken for donations and subscriptions when they are received. Credit is taken for legacies when received or if, before receipt, there is sufficient evidence to provide the necessary certainty that the legacy will be received and the value of the incoming resources can be measured with sufficient reliability.

Other trading activities

Fundraising income - represents gross income from events.

Subsidiary's non-charitable trading turnover - represents gross income from York Against Cancer Trading Company Limited, the Charitable Company's trading subsidiary.

Investments

Investment income has been accounted for on an accruals basis.

Expenditure

Raising funds

Fundraising costs - represents the total costs of fundraising events and activities held during the year.

Non charitable trading expenditure - comprises of the direct costs and administrative costs of the Charitable Company's trading subsidiary, York Against Cancer Trading Company Limited.

Charitable activities

Direct costs - comprises of expenditure on various projects the Charitable Company is supporting and is accounted for in full when the Charitable Company commits to provide the funding.

Support costs - comprises of the salaries and office expenses of the Charitable Company.

Governance costs - comprises the costs associated directly with the management by the Directors/Trustees of the Charitable Company's activities, including audit fees and costs of meetings.

All costs are apportioned on an actual cost basis.

23

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

1. ACCOUNTING POLICIES (continued)

Pension costs

The Charitable Company operates a defined contribution money purchase pension scheme for specific employees. The assets of the scheme are invested and managed independently of the finances of the Charitable Company. The charge for pension costs represents the contributions payable in the year.

Fixed Assets

Individual fixed assets costing £200 or more are capitalised and included in the accounts at cost.

Tangible fixed assets are depreciated over their expected useful lives at the following annual rates:

Freehold/Leasehold property at straight line over 50 years Equipment - Shop and office equipment at straight line over 10 years - Computer equipment at straight line over 3 years - Respite home equipment at straight line over 4 years Motor vehicles at 25% reducing balance

Stock

Stock is valued at the lower of cost and net realisable value. Cost is computed on a first in first out basis. Net realisable value is based on estimated selling price less the estimated cost of disposal.

Funds Structure

Unrestricted Funds are funds which are available for use or retention at the discretion of the Directors/Trustees, in accordance with the Charity's objects. Designated Funds represent unrestricted funds earmarked by the Directors/Trustees for particular purposes. Restricted Funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal. Details of Designated and Restricted Funds are contained in Notes 16 and 17, respectively.

Investments

The investment portfolios have been valued at market value at 31 December 2020. The SOFA includes the net gains and losses on investments arising on revaluation at the year end and on disposals throughout the year. Realised gains and losses on sales of investments are calculated as the difference between the sale proceeds and opening market value. Unrealised gains and losses represent the movement between market values.

Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand

Cash at bank and cash in hand includes cash and any short term deposit accounts with a maturity of three months or less from the date of opening.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Operating Leases

Rentals paid under operating leases are charged in the SOFA on a straight line basis over the lease term.

24

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2020

2.

DONATIONS AND LEGACIES
In Memoriam
Legacies
Government grant
Intangible income
Donations		 Unrestricted
Restricted
2020
£
£
£
117,589
600
118,189
24,957
-
24,957
13,225
-
13,225
21,334
21,334
5,000
-
5,000
£ 182,105
£ 600
£ 182,705		 2019
£
155,183
32,312
1,168,941
-
9,096
£ 1,365,532

Intangible income comprises accounting services, a proportion of which is provided free of charge for the preparation of the Charitable Company and Subsidiary statutory accounts. A corresponding amount is included within governance costs.

3. OTHER TRADING ACTIVITIES

OTHER TRADING ACTIVITIES
Fundraising income
Subsidiary's non-charitable trading turnover
Miscellaneous income
INVESTMENTS
Interest received
Dividends received
ANALYSIS OF RAISING FUNDS
Advertising
Fundraising costs
Non charitable trading expenditure
Investment fees		 Unrestricted
Restricted
£
£
7,900
-
65,847
-
70,995
-
11,914
-		 2020
£
72,639
85,224
-
£ 157,863
2020
£
2,696
46,595
£ 49,291
2020
£
7,900
65,847
70,995
11,914
£ 156,656		 2019
£
150,469
123,483
66
£ 274,018
2019
£
3,463
65,570
£ 69,033
2019
£
13,181
77,106
81,865
13,940
£ 156,656
£ -		 £ 186,092

4.

5.

25

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

6. ANALYSIS OF CHARITABLE ACTIVITES

Direct project costs:
Research
Jack Birch Unit
Clinical Trial Nurses
Support and Care
Cancer Care Centre
Complementary therapy
Health Care Assistant
Respite property expenses
Minibus running costs
Mobile Chemotherapy Unit
Psychology services
Restricted grants
Family Support Worker
Health Welfare Advisor
Hospital equipment
Education
Education expenses
Support costs:
Staff costs
Staff training and travel
Rent and rates
Heat and light
Repairs and maintenance
Insurances
Printing, stationery and postage
Computer expenses
Telephone
Sundry expenses
Depreciation
Governance costs:
Audit fees
Accountancy fees
Bank charges
Total charitable activities
Release of committed projects		 Unrestricted
Restricted
2020
£
£
£
-
-
-
19,239
-
19,239
26,330
-
26,330
29,541
-
29,541
7,865
7,865
29,257
-
29,257
25,562
-
25,562
-
321
321
5,680
-
5,680
-
12,222
12,222
-
-
-
-
-
-
-
-
-
-
-
-
7,170
-
7,170
150,644
12,543
163,187
157,081
-
157,081
1,702
-
1,702
4,352
-
4,352
1,666
-
1,666
1,932
-
1,932
2,963
-
2,963
4,856
-
4,856
7,867
-
7,867
1,710
-
1,710
3,953
-
3,953
16,015
-
16,015
204,097
-
204,097
3,480
-
3,480
7,663
-
7,663
1,563
-
1,563
12,706
-
12,706
£ 367,447
£ 12,543
£ 379,990		 2019
£
1,413,264
127,478
47,803
44,003
13,052
41,315
21,122
-
-
-
22,379
95,000
35,473
(96,508)
26,353
1,790,734
156,400
3,597
12,773
1,668
1,073
3,374
3,943
8,425
1,514
4,407
16,632
213,806
3,480
11,596
1,184
16,260
£ 2,020,800

26

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

7. NET INCOMING RESOURCES FOR THE YEAR
NET INCOMING RESOURCES FOR THE YEAR 2020 2019
£ £
This is stated after charging:
Depreciation 18,530 18,849
Auditor's remuneration for audit services 3,480 3,480

8. REMUNERATION AND EXPENSES OF TRUSTEES

None of the Trustees received any remuneration or benefits by virtue of being a trustee of the Charity and no Trustees were reimbursed any expenses incurred for services provided to the Charity.

9. STAFF COSTS

Wages and salaries
Social security costs
Pension costs
Medical Insurance		 2020
£
155,368
8,710
7,104
4,432
£ 175,614		 2019
£
137,566
8,181
6,143
4,510
£ 156,400

The average monthly head count was 8 staff (2019 8) and the average monthly number of full-time equivalent employees (including casual and parttime staff) during the year were as follows:

Management and administration of the Charitable Company

7 7

No employee received emoluments in excess of £60,000.

The key management personnel of the Charitable Company, comprise the directors and trustees and the General Manager. The total employee benefits of the key management personnel of the Charitable Company were £49,937 (2019 - £49,196).

10. SUBSIDIARY COMPANY

The Charitable Company owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited. This company is registered in England and Wales (reg. no. 3405708) and its registered office is 31 North Moor Road, Huntington, York, YO32 9QN. The subsidiary is used for the raising of funds for the Charitable Company through the sale of bought in goods through the Charitable Company's shop and stalls. All activities have been consolidated on a line by line basis in the SOFA.

There is a loan account between the Charitable Company and the subsidiary. The balance on the loan account outstanding at the year end was £95,637 (2019 £93,645). Interest of £141 (2019 £1,355) was charged during the year in respect of this loan.

A summary of the results of the subsidiary is shown below:

ummary of the results of the subsidiary is shown below:
Turnover
Cost of sales
Gross profit
Administrative expenses
Operating profit
Other operating income
Interest payable
Profit on ordinary activities before taxation
Taxation
Profit on ordinary activities after taxation
Amount gifted to York Against Cancer
Retained within/(withdrawn from) Subsidiary
Net Assets		 2020
£
85,224
(46,891)
38,333
(48,953)
(10,620)
11,334
(141)
573
-
573
-
£ 573
£ 37,063		 2019
£
123,483
(53,112)
70,371
(62,391)
7,980
-
(1,355)
6,625
-
6,625
-
£ 6,625
£ 36,490

27

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2020

11. INVESTMENTS

ESTMENTS
Consolidated
Market value at 1 January 2020
Additions at cost
Disposals
Revaluations
Market value at 31 December 2020
Analysis of investments by class:
Listed investments
The historical cost of the above investments amounts to:		 2020
£
3,548,076
1,117,345
(1,095,488)
171,077
£ 3,741,010
3,741,010
£
3,521,243
£		 2019
£
3,666,711
825,288
(1,295,325)
351,402
£ 3,548,076
3,548,076
£
3,521,243
£

The following material investments are over 5% by value of the investments held

HSBC FTSE All Share Index
Ruffer Charity Assets Trust Account		 2020
Market value
£
302,095
2,010,192
£ 2,312,287		 2019
Market value
£
278,825
1,798,655
£ 2,077,480

The Charitable Company holds all of the issued shares of its subsidiary undertaking York Against Cancer Trading Company Limited, at cost of £1, in addition to the above investments.

12. TANGIBLE FIXED ASSETS
Depreciation
Cost
At 1 January 2020
Additions in year
At 31 December 2020
At 31 December 2020
At 31 December 2019
At 1 January 2020
Charge for year
At 31 December 2020
Net book value		 Subsidiary -
Motor
Charity
Shop
Property
Vehicles
Equipment
Total
Equipment
£
£
£
£
£
635,602
41,515
46,469
723,586
31,881
-
-
-
-
2,990
635,602
41,515
46,469
723,586
34,871
60,015
34,096
39,934
134,045
20,540
12,712
1,855
1,448
16,015
2,515
72,727
35,951
41,382
150,060
23,055
£ 562,875
£ 5,564
£ 5,087
£ 573,526
£ 11,816
£ 575,587
£ 7,419
£ 6,535
£ 589,541
£ 11,341		 Consolidated
Total
£
755,467
2,990
758,457
154,585
18,530
173,115
£ 585,342
£ 600,882

All fixed assets are held for direct charitable purposes in Designated Funds.

28

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

13.
Amounts owed by subsidiary
Prepayments
Accrued income
Other debtors
14. CREDITORS: amounts falling due
within one year
Trade creditors
Project creditors
Taxation and social security
Accruals
Other creditors
15. CREDITORS: amounts falling due
after one year
Project creditors
DEBTORS		 Charity
Consolidated
Charity
Consolidated
2020
2020
2019
2019
£
£
£
£
95,637
-
93,645
-
9,250
13,902
9,709
14,234
446,909
448,243
680,096
680,096
140
140
-
-
£ 551,936
£ 462,285
£ 783,450
£ 694,330
30,378 33,524 31,117 36,685
444,038
444,038
561,184
561,184
3,128
8,730 3,495
7,582
8,893
11,693 18,227
21,027
1,122
1,122
1,148
1,148
£ 487,559
£ 499,107
£ 615,171
£ 627,626
£ 961,016
£ 961,016
£ 1,252,278
£ 1,252,278

16.[DESIGNATED FUNDS (consolidated)]

The Charitable Company transfers to designated funds sufficient resources to meet such commitments, as shown below.

Designated Funds - 2020
Cancer Care Centre
Complementary Therapy
Education Project
Minibus
Patient Travel
Fixed Assets Fund
Total
Designated Funds - 2019
Cancer Care Centre
Complementary Therapy
Education Project
Fixed Assets
Total		 Balance
Income
Expenditure
Transfers
Balance
01/01/2020
31/12/2020
£
£
£
£
£
31,500
-
(26,118)
-
5,382
35,480
-
(29,116)
-
6,364
-
-
(7,170)
7,170
-
-
-
-
28,000
28,000
-
-
-
10,000
10,000
600,882
-
(18,530)
2,990
585,342
£ 667,862
£ -
£ (80,934)
£ 48,160
£ 635,088
Balance
Income
Expenditure
Transfers
Balance
01/01/2019
31/12/2019
£
£
£
£
£
-
-
(18,900)
50,400
31,500
-
-
(21,288)
56,768
35,480
-
-
(26,353)
26,353
-
609,805
-
(18,849)
9,926
600,882
£ 609,805
£ -
£ (85,390)
£ 143,447
£ 667,862

Cancer Care Centre

The Board is committed to a service level agreement with York Hospital to provide the funding for 3 administrator posts from 1 April 2019 to 31 March 2021.

29

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2020

16.[DESIGNATED FUNDS (consolidated continued)]

Complementary Therapy

The Board is committed to a service level agreement with York Hospital to provide the funding for a therapist post from 1 April 2019 to 31 March 2021.

Minibus

The trustees have set aside monies for the purchase of a new minibus which will be purchased next year.

Patient Travel

The trustees have set aside monies to fund Patient Travel and this will be reviewed next year once demand is known.

Fixed Asset Fund

This fund represents funds invested in tangible fixed assets.

Education Project

The Board agreed to fund the annual budgeted costs of the Education Project which is aimed at raising the awareness of cancer to the public.

17. RESTRICTED FUNDS (consolidated)

Restricted Funds - 2020
Mobile Chemotherapy Unit
Prostate Cancer
Mouth Cancer
Total 2020
Restricted Funds - 2019
Minibus Appeal
Mobile Chemotherapy Unit
Prostate Cancer
Mouth Cancer
Total 2019		 Balance
Income
Expenditure
Transfers
Balance
01/01/2020
31/12/2020
£
£
£
£
£
142,069
600
(321)
-
142,348
12,222
-
(12,222)
-
-
1,677
-
-
-
1,677
£ 155,968
£ 600
(£ 12,543)
£ -
£ 144,025
Balance
Income
Expenditure
Transfers
Balance
01/01/2019
31/12/2019
£
£
£
£
£
6,898
-
(6,898)
-
-
139,046
3,023
-
-
142,069
-
12,222
-
-
12,222
-
1,677
-
-
1,677
£ 145,944
£ 16,922
(£ 6,898)
£ -
£ 155,968

Minibus Appeal

The Minibus Appeal relates to funds raised for the specific purpose of purchasing and running a minibus to transport cancer patients between York Hospital and Cookridge Hospital in North Leeds.

Mobile Chemotherapy Unit

The Mobile Chemotherapy Unit Appeal relates to funds raised for the specific purpose of running the service.

Prostate Cancer

50% of the R U taking the P monies raised where to be allocated to prostate cancer research.

Mouth Cancer

Monies raised for the Head and Neck cancer department.

30

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

18. ANALYSIS OF GROUP NET ASSETS BETWEEN FUNDS

Fund balances at 31 December 2020
are represented by:
Tangible fixed assets
Investments
Current assets
Current liabilities
Long term liabilities
Fund balances at 31 December 2019
are represented by:
Tangible fixed assets
Investments
Current assets
Current liabilities
Long term liabilities		 General
Designated
Restricted
Total
Funds
Funds
Funds
2020
£
£
£
£
-
585,342
-
585,342
3,741,010
-
-
3,741,010
1,222,644
49,746
144,025
1,416,415
(499,107)
-
-
(499,107)
(961,016)
-
-
(961,016)
£ 3,503,531
£ 635,088
£ 144,025
£ 4,282,644
General
Designated
Restricted
Total
Funds
Funds
Funds
2019
£
£
£
£
-
600,882
-
600,882
3,548,076
-
-
3,548,076
1,833,332
-
155,968
1,989,300
(627,626)
-
-
(627,626)
(1,252,278)
-
-
(1,252,278)
£ 3,501,504
£ 600,882
£ 155,968
£ 4,258,354

19. OPERATING LEASE COMMITMENTS

As at 31 December 2020 the charitable company had future minimum lease payments under non-cancellable operating leases as follows:

At 31 December 2020 At 31 December 2020 At 31 December 2019 At 31 December 2019
Land and Office Land and Office equipment
buildings equipment buildings
£ £ £ £
Operating leases which expire:
Within one year 15,000 - 15,000 -
Between two and five years - - 7,500 -

20. RELATED PARTIES

During the year the Charitable Company paid £2,620 (2019 £2,493) to HPH Chartered Accountants for accountancy services and software costs, a firm in which the Charitable Company's Treasurer, Sarah Wearing, is a partner. At the year end there was £nil (2019 £nil) owing to HPH Chartered Accountants.

31

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

21. RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES

Net income/(expenditure) for the reporting period
Adjustments for:
Depreciation charges
(Gains)/Losses on investments
Dividends, interest and rents from investments
Increase in stocks
Increase in debtors
(Increase)/Decrease in creditors
Net cash provided by/(used in) operating activities
ANALYSIS OF CASH AND CASH EQUIVALENTS
Cash at bank and in hand
Total cash and cash equivalents		 2020
2019
£
£
24,290
(146,907)
18,530
18,849
(171,077)
(351,402)
(49,291)
(69,033)
1,964
(14,524)
232,045
(576,507)
(419,781)
1,145,730
£ (363,320)
£ 6,206
898,835
1,237,711
£ 898,835
£ 1,237,711

22. VOLUNTEERS

The Charity is fortunate to be supported by over 100 volunteers. Their activities include working in our shops, attending events, supporting the office, collections and baking. Without them the Charity could not achieve what it does; their support is a massive asset in both workforce and financial terms. Whilst going about their work they are also ambassadors for the Charity which encourages more people to volunteer and support.

With varied knowledge, skills and experience the volunteers make an invaluable group. Our thanks goes to them all – together we really do make a difference to cancer patients and their families.

32

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

24. COMPARATIVE INFORMATION

Income and endowments from:
Donations and legacies
Other trading activities
Investments
Total
Expenditure on:
Raising funds
Charitable activities
Total
Net income/(expenditure)
before losses on investments
Net gains/(losses) on investments
Net income/(expenditure)
Transfers between funds
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Total funds carried forward		 General
Designated
Fund
Funds
£
£
1,348,610
-
274,018
-
69,033
-
1,691,661
-
186,092
-
1,928,512
85,390
2,114,604
85,390
(422,943)
(85,390)
351,402
-
(71,541)
(85,390)
(143,447)
143,447
(214,988)
58,057
3,649,512
609,805
3,434,524
£
667,862
£
Unrestricted		 Restricted
Funds
£
16,922
-
-
16,922
-
6,898
6,898
10,024
-
10,024
-
10,024
145,944
155,968
£		 Year ended
31 Dec
2019
£
1,365,532
274,018
69,033
1,708,583
186,092
2,020,800
2,206,892
(498,309)
351,402
(146,907)
-
(146,907)
4,405,261
4,258,354
£

33